淋巴细胞核DNA-吖啶橙体系荧光抑制法筛选抗癌药物的研究  

Study on Screening of Anticancer Drugs by Lymphocyte Nuclear FDNA Acridine Orange System Fluorescence Inhibition

作　　者：陈蓓[1] 唐宏武[1] 陈观铨[1] 叶勇 曾云鹗[1] 

机构地区：[1]武汉大学化学系

出　　处：《分析科学学报》1997年第1期1-5,共5页Journal of Analytical Science

基　　金：国家自然科学基金;湖北省自然科学基金

摘　　要：以人外周血淋巴细胞为标准细胞，用荧光探针吖啶橙（ＡＯ）示踪药物和细胞ＤＮＡ的作用，提出一种用Ｈａｄａｍａｒｄ变换显微荧光图象分析法初步筛选抗癌药物的新方法．对五种临床细胞周期非特异性抗癌药物（ＣＣＮＳＡ）的实验结果和药物与细胞ＤＮＡ作用的原理相符，表明此方法适用于筛选此类抗癌药物．对四种氯代苯甲醛丙氨酸Ｓｃｈｉｆ碱（ＣＡ）金属配合物与淋巴细胞ＤＮＡ作用，研究结果表明：３－ＣＡＣｏ、３－ＣＡＺｎ、２－ＣＡＫ和４－ＣＡＫ均能与细胞核ＤＮＡ发生一定程度的作用，但对Ｇ０期淋巴细胞敏感性较差．Using human lymphocyte as standard cell and acridine orange (AO) to trace the interaction of drug and cellular DNA, a novel method for preliminary screening of anticancer drugs by Hadamard transform microscopic fluorescence image analysis is developed. The results for five Cell Cycle Nonspecific Agents (CCNSA) are in accordance with the mechanism of the drugs binding to cellular DNA, this indicates that this method is suitable for screening anticancer drugs of this kind. The study of four metal complexes of Schiff bases derived from chlorobenzaldehyde and L alanine shows that: all of the four compounds 3 CACo 、3 CAZn、2 CAK and 4 CAK can bind to nuclear DNA to an extent, but they are not sensitive for G 0 phase lymphocyte.

关 键 词：吖啶橙 淋巴细胞核DNA 萤光抑制 抗癌药物 筛选 

分 类 号：R979.1[医药卫生—药品] R965.1[医药卫生—药学]